Novabridge Biosciences (NASDAQ:NBP) Insider Mark Arnold Hagler Purchases 46,000 Shares of Stock

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) insider Mark Arnold Hagler purchased 46,000 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average cost of $0.34 per share, with a total value of $15,640.00. Following the completion of the acquisition, the insider owned 276,000 shares in the company, valued at approximately $93,840. This trade represents a 20.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Arnold Hagler also recently made the following trade(s):

  • On Wednesday, November 18th, Mark Arnold Hagler purchased 184,000 shares of Novabridge Biosciences stock. The shares were purchased at an average price of $0.38 per share, with a total value of $69,920.00.

Novabridge Biosciences Stock Performance

NBP opened at $0.88 on Friday. Novabridge Biosciences has a one year low of $0.75 and a one year high of $5.19. The company has a fifty day moving average price of $1.26 and a 200-day moving average price of $1.98.

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) last issued its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Novabridge Biosciences will post -0.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novabridge Biosciences in a research note on Thursday, August 27th. Wall Street Zen raised Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Novabridge Biosciences in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Novabridge Biosciences presently has an average rating of “Hold” and a consensus target price of $9.00.

Check Out Our Latest Research Report on Novabridge Biosciences

About Novabridge Biosciences

(Get Free Report)

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.

Featured Stories

Insider Buying and Selling by Quarter for Novabridge Biosciences (NASDAQ:NBP)

Receive News & Ratings for Novabridge Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabridge Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.